Fundamental and clinical studies on the efficacy of Pazufloxacin for tonsillitis and pharyngolarygitis

Abstract

Fundamental and clinical studies on the efficacy of Pazufloxacin (PZFX) for tonsillitis and pharyngolarygitis were performed in a multicenter cooperative system with the following results:
1. The concentration of PZFX administered at a single oral dose of 200mg was 0.04-1.68μg/g (0.68-0.81; ration to the serum level) and 0.40-2.04μg/g (0.21-1.22) in the tonsil and submandibular gland, respectively, which thus indicated food tissue penetration.
2. The efficacy rate was 85% (29/34) for lacunar tonsillitis, 4/7 for peritonsillitis, and 5/5 for pharyngolaryngitis.
3. The bacteriological eradication rate was 100% (28/28) in monomicrobial infection and 8/9 in polymicrobial infection.
4. The MIC values of PZFX against the total clinical isolates ranged from≤0.025-6.25μg/ml, which were almost equal to those of Ofloxacin (OFLX).
5. Adverse reactions were only observed in 2 of 57 cases (1 case each of diarrhea and skin rash, respectively) and they were moderate or slight in severity. Abnormal laboratory findings were observed in 4 cases (1 case respectively of elevated GPT, eosinophilia, an elevated urinary sugar level, and an elevated level of GOT·GPT·ALP·γ-GTP and urinary protein).
These results therefore suggest that PZFX is a very useful drug for the treatment of tonsillitis and pharyngolaryngitis.